Canswerist

âThis is a phenomenal example of finding the right patient and the right drug very early on,â said Dr. Pasi A. Janne of the Dana-Farber Cancer Institute in Boston, who was involved in the trial that is cited by the following report. clipped from www.nytimes.com CHICAGO — Using two opposite strategies, scientists say they have made significant progress in taming two of the most intractable types of cancer . One approach, highly focused on specific types of tumors , shrank them significantly in 57 percent of patients with a lung cancer marked by a specific genetic abnormality. Even though the clinical trial was small (just 82 people, with no control group), the results were considered so striking for such sick patients that the study will be featured Sunday at the main session of the annual meeting of the American Society of Clinical Oncology here. Well Five Rice Dishes to Steam Up Your Table June 4, 2010 Getting Audited by Your Health Insurer June 4, 2010 Making Sure...

City of Hope is one of the world's largest and most renowned cancer research and treatment centers. On any given hour of virtually any day, thousands of people are walking through or waiting in these vast corridors. Yesterday, I was one of them. Yes, this was the latest of numerous trips to the hospital, this was the first trip in which I had this solitary thought: "I had cancer. I do not have it now." My reason for visiting the hospital was to receive an infusion of immunoglobulin, a periodic treatment that helps to boost my immune system and increase my chances for long-term remission. But while waiting for this appointment in the hospital corridor outside of the infusion center, in proximity I noticed two couples in silence and expectation. Seated to my far left was a slightly woman resting her head on her husband's shoulder while trying to doze amid the sounds and clatter of passersby. And closest to me was a young Hispanic woman in a wheel chair to which w...

Granted, our trips to City of Hope and to regular physician appointments have greatly diminished this spring and summer and we hope and pray that this progress continues for a long time. clipped from altaloman.amplify.com Due tomorrow at City of Hope is my appointment for five of six in the series of immunoglobulin infusions that, so far, have been helpful in boosting my immune system and my overall return to health. What a benefit this therapy is for my health maintenance.  Dee Dee and I have noticed a great difference (mainly the absence of respiratory distress) since these monthly  treatments began in February.   The long-term proof will be when the series ends next month and what happens in the weeks and months that follow, but we are expecting that our status will remain positive and healthful. || @LINK ||   MyJournal  

Phase III Study Showed First-Line Maintenance Use of Rituxan Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening || http://bit.ly/atkD7r || http://bit.ly/dd2UJg clipped from www.gene.com Rituxan is a therapeutic antibody that binds to a specific protein called CD20 found on the surface of cancerous and normal B-cells. In NHL and rheumatoid arthritis (RA), Rituxan works with the body's own immune system to eliminate marked CD20-positive B-cells. Stem cells (B-cell progenitors, those cells that give rise to B-cells) in bone marrow do not have the CD20 protein. B-cells usually regenerate after Rituxan treatment and return to normal levels in about 12 months for most patients.  

Cancer experts warn you may as well smoke a cigarette if you want a healthy tan | Mail Online : "Leading oncologists are warning of a skin cancer epidemic where young women are particularly at risk We have just endured one of the longest winters for many years. Then the sun came out. Hatless, sleeveless, heedless, the human reaction to the warming sun was to turn our face towards it. Sunlight soothes, delights... and, increasingly, kills. The incidence and death rates of malignant melanoma - the deadliest skin cancer - are inexorably rising. 'You can call it, for want of a better word, an epidemic,' says Richard Marais, professor of molecular oncology at The Institute of Cancer Research in London."